España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Ovid Therapeutics
OVID
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.9991
-0.02
-2.05%
At close: -
$0.9991
0.00
0.00%
After Hours: Dec 20, 4:03 PM EDT
Get Report
Comment
Ovid Therapeutics (OVID) Forecast
News
Earnings
Ovid Therapeutics (OVID) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Ovid Therapeutics (NASDAQ:OVID) Stock
Ovid Therapeutics Stock (NASDAQ: OVID)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 04, 2024
HC Wainwright & Co. Reiterates Buy on Ovid Th...
Benzinga Newsdesk
Tuesday, November 12, 2024
Ovid Therapeutics Q3 EPS $(0.20) Misses $(0.1...
Benzinga Newsdesk
Ovid Therapeutics Q3 2024 GAAP EPS $(0.20) Mi...
Benzinga Newsdesk
Wednesday, October 16, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
Monday, September 30, 2024
HC Wainwright & Co. Reiterates Buy on Ovid Th...
Benzinga Newsdesk
Thursday, September 26, 2024
Ovid Therapeutics Presents Pre-Clinical Study...
Benzinga Newsdesk
Wednesday, September 11, 2024
Ovid Therapeutics Promotes Meg Alexander To P...
Benzinga Newsdesk
Monday, August 19, 2024
Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Ovid Th...
Benzinga Newsdesk
Friday, July 26, 2024
The Latest Analyst Ratings For Ovid Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Ovid Th...
Benzinga Newsdesk
Wednesday, July 10, 2024
Ovid Therapeutics Announces eNeuro Publishes ...
Benzinga Newsdesk
Tuesday, July 02, 2024
HC Wainwright & Co. Reiterates Buy on Ovid Th...
Benzinga Newsdesk
Monday, July 01, 2024
Ovid Therapeutics And Graviton Bioscience Ann...
Benzinga Newsdesk
Tuesday, June 18, 2024
BTIG Maintains Buy on Ovid Therapeutics, Lowe...
Benzinga Newsdesk
B. Riley Securities Maintains Buy on Ovid The...
Benzinga Newsdesk
Citigroup Maintains Neutral on Ovid Therapeut...
Benzinga Newsdesk
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Ovid The...
Benzinga Newsdesk
Monday, June 17, 2024
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
Avi Kapoor
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
Avi Kapoor
US Stocks Mixed; Dow Tumbles Over 100 Points
Avi Kapoor
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Vandana Singh
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Ovid Therapeutics shares are trading lower af...
Benzinga Newsdesk
After Takeda's Phase 3 Topline Study Results ...
Benzinga Newsdesk
Takeda Announced Topline Data From SKYLINE An...
Benzinga Newsdesk
Thursday, May 16, 2024
HC Wainwright & Co. Reiterates Buy on Ovid Th...
Benzinga Newsdesk
Tuesday, May 14, 2024
Alimera Sciences Reports Q1 Loss, Misses Revenue Estimates
Zacks
Ovid Therapeutics Q1 EPS $(0.17) Beats $(0.21...
Benzinga Newsdesk
Tuesday, May 07, 2024
Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics
Benzinga Insights
Citigroup Maintains Neutral on Ovid Therapeut...
Benzinga Newsdesk
Tuesday, April 30, 2024
B. Riley Securities Initiates Coverage On Ovi...
Benzinga Newsdesk
Monday, April 29, 2024
HC Wainwright & Co. Initiates Coverage On Ovi...
Benzinga Newsdesk
Wednesday, April 24, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Friday, April 05, 2024
Wedbush Initiates Coverage On Ovid Therapeuti...
Benzinga Newsdesk
Thursday, March 21, 2024
Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Avi Kapoor
Friday, March 08, 2024
Recap: Ovid Therapeutics Q4 Earnings
Benzinga Insights
Ovid Therapeutics Q4 2023 GAAP EPS $(0.220) M...
Benzinga Newsdesk
Thursday, January 11, 2024
Ovid Therapeutics Filed U.S. Patent Application #20240009160: Use Of (S)-3-amino-4-(Difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid In The Treatment Of Cancer
Charles Gross
Thursday, December 21, 2023
BTIG Initiates Coverage On Ovid Therapeutics ...
Benzinga Newsdesk
Wednesday, November 15, 2023
Ovid Therapeutics Inc Says May Offer And Sell...
Benzinga Newsdesk
Friday, November 03, 2023
Ovid Therapeutics Inc Files For Mixed Shelf O...
Benzinga Newsdesk
Ovid Therapeutics Q3 EPS $(0.16) Beats $(0.19...
Benzinga Newsdesk
Wednesday, October 18, 2023
Ovid Therapeutics and Ligand Pharma Ink a $30...
Benzinga Newsdesk
Monday, August 21, 2023
Marinus Pharmaceuticals Said On August 17, The PTAB Granted Co's Petition Seeking Post-grant Review Of Ovid Therapeutics' U.S. Patent No. 11,395,817
Charles Gross
Friday, August 04, 2023
Ovid Therapeutics' Q2 Cash, Cash Equivalents ...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch